Dr. Yilie Liao | Metabolism | Best Researcher Award

Dr. Yilie Liao, Zhongshan Institute for Drug Discovery (ZIDD), China

Yilie Liao is an accomplished scientist specializing in metabolic research and integrative biology. Currently, she serves as an Assistant Research Scientist at the Zhongshan Institute for Drug Discovery under the Shanghai Institute of Materia Medica, part of the Chinese Academy of Sciences. With a Ph.D. in Biology from Tsinghua University, Yilie has a rich background in life sciences, particularly focusing on metabolic disease, neurodevelopment, and tumorigenesis. Her research, conducted in collaboration with leading institutions, including Duke-NUS Medical School, delves into metabolic reprogramming, revealing significant insights into the biological mechanisms underlying health and disease. She is recognized for her innovative approach, evidenced by her pioneering work in metabolic pathways and proteomic studies. Through her dedication to research and collaboration, Yilie continues to push the boundaries of biological sciences, making notable contributions to the understanding and potential treatments for complex metabolic conditions.

Professional Profile

Orcid

Suitability for the Research for Best Researcher Award

Yilie Liao’s dedication to addressing vital biological questions in metabolic health and his breadth of expertise in both technical and conceptual aspects of biology position him as an exceptional candidate for the Research for Best Researcher Award. His innovative findings, technical versatility, and contributions to high-impact publications underscore his potential for continued advancements in biology.

Education

Yilie Liao obtained her Ph.D. in Biology from the School of Life Sciences at Tsinghua University in 2020, where she conducted groundbreaking research under the mentorship of Dr. Suneng Fu. Her doctoral studies focused on metabolic reprogramming in metabolic diseases and neural development. Previously, she earned her B.Sc. in Biological Science from Nanjing Agricultural University in 2013. Her undergraduate education laid the foundation for her interest in integrative biology and metabolic research. Throughout her academic journey, Yilie acquired a robust skill set, encompassing molecular biology techniques, data analysis, and metabolomic profiling. Her proficiency in multi-omics data analysis, combined with a strong foundation in biological sciences, has enabled her to explore complex biochemical pathways and cellular processes. Her educational background reflects her commitment to advancing scientific knowledge and tackling complex issues in metabolic diseases and cellular biology.

Experience

Yilie Liao’s research career spans several prestigious institutions and roles, each contributing to her expertise in metabolic biology. She is currently an Assistant Research Scientist at Zhongshan Institute for Drug Discovery under the Shanghai Institute of Materia Medica. From 2021 to 2023, she worked as a Postdoctoral Fellow at Bioland Laboratories, investigating neurodevelopmental and metabolic disease mechanisms under Prof. Peng Li. In 2022, she was a visiting researcher at Duke-NUS Medical School, exploring novel metabolic pathways with renowned scientists Prof. Weiping Han and Dr. Alfred Sun. Her projects have included identifying SLC transporters in the central nervous system and studying metabolic substrates impacting liver and brain health. Through these roles, Yilie has acquired extensive experience in experimental design, data mining, and integrative biology, making her a leading expert in her field with substantial contributions to metabolic disease research.

Awards and Honors

Yilie Liao’s contributions to metabolic biology and her dedication to advancing scientific understanding have earned her numerous accolades. Her work on hepatic lipogenesis and metabolic reprogramming has been recognized with prestigious awards from leading scientific societies, highlighting her impact in biomedical research. She has received notable recognition from the Chinese Academy of Sciences for her innovative work in translational research and metabolic disease. As a testament to her expertise, she has been a recipient of research grants supporting her studies on cellular metabolism, neurodevelopment, and tumorigenesis. Yilie’s publications in high-impact journals such as Cell Metabolism and Hepatology further underscore her prominence in the field. Her academic and professional honors reflect her commitment to scientific excellence and her potential to drive significant advancements in biological and metabolic research.

Research Focus

Yilie Liao’s research centers on uncovering the intricate mechanisms of metabolic reprogramming in health and disease. She investigates how metabolic pathways influence conditions such as obesity, neurodevelopmental disorders, and cancer, with a particular focus on the role of amino acids in hepatic lipogenesis. Her recent work explores SLC transporters’ influence in the central nervous system and their impact on brain functions. Additionally, her research extends to the identification of metabolic markers in Alzheimer’s disease, using single-cell sequencing to reveal early dysfunctions. She is also involved in studying tumor microenvironment metabolic changes, with implications for early diagnosis and treatment of liver cancer. Through her work, Yilie aims to provide insight into metabolic diseases and develop novel therapeutic approaches that address metabolic imbalances, contributing to the broader field of translational medicine.

Publication Top Notes

Amino acid is a major carbon source for hepatic lipogenesis
Hepatic mitochondrial NAD+ transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis
Genetic Ablation of LAT1 Inhibits Growth of Liver Cancer Cells and Downregulates mTORC1 Signaling

Prof. Dr. Abhay H Pande, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Punjab, India

Abhay H Pande is a distinguished professor at the National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Punjab. He leads the Protein Biopharmaceutical Lab, where his work focuses on the development of innovative biopharmaceuticals targeting inflammatory disorders, cancer, and bioterrorism defense. Notable advancements include the development of bispecific antibodies and prophylactic biologics like LBUPON™. With 18 patents and over 80 scientific publications, Pande’s research has gained global recognition. He is also deeply committed to bridging academia and industry, playing a key role in incubation initiatives such as CPIE and BioNEST. His passion for teaching is reflected in his contributions to curriculum development and mentoring numerous Ph.D. and Master’s students. Pande is recognized for his leadership in pharmaceutical innovation, sustainability, and promoting biotechnology’s role in global health solutions.

Summary of Suitability for the Award

Dr. Abhay H. Pande is highly suitable for the Research for Best Researcher Award based on his extensive and impactful contributions to the field of biopharmaceuticals. As a professor at the National Institute of Pharmaceutical Education and Research (NIPER), his innovative research focuses on developing novel biologics for critical healthcare challenges, including cancer, inflammatory diseases, and bioterrorism defense. His work has led to the development of pioneering biologics such as BiSpekDAb™, ApoEFrag™, and LBUPON™, which are in advanced pre-clinical stages, showcasing his expertise in translating scientific discoveries into real-world solutions.

Education

Abhay H Pande completed his education in biopharmaceutical sciences, with a strong emphasis on biotechnology and pharmaceutical development. His academic journey equipped him with the knowledge and skills to develop biopharmaceutical solutions to address global healthcare challenges. Over the years, he has designed comprehensive curricula for M.Tech programs in Biopharmaceuticals and Medical Devices, reflecting his expertise in interdisciplinary fields like biochemistry, biotechnology, immunology, and cell biology. Pande’s academic foundation and continuous learning have fueled his innovative work in developing therapeutics for cancer, inflammatory disorders, and bioterrorism defense. His teaching and curriculum design efforts further demonstrate his dedication to education and the dissemination of biopharmaceutical knowledge.

Experience

Abhay H Pande has over two decades of experience in the pharmaceutical and biotechnology fields, currently serving as a professor at NIPER. He has led numerous research projects aimed at developing innovative biologics, such as bispecific antibodies and anticancer biologics. Pande has also held leadership roles as the chairman of the CPIE-Incubation Center and project coordinator for BioNEST, where he fosters collaboration between academia and industry. His experience includes teaching courses in Biochemistry, Biotechnology, Immunology, and Cell Biology, as well as supervising the research of 9 Ph.D. scholars and 138 master’s theses. His contributions span across research, innovation, and academic leadership.

Awards and Honors

Abhay H Pande has been recognized for his groundbreaking work in biopharmaceuticals through numerous awards and honors. He has secured 18 patents for his innovative biologics and therapeutic developments. His research contributions have been honored at prestigious national forums, reflecting the widespread recognition of his work. Additionally, Pande has been invited to deliver lectures globally on biotechnology’s role in sustainability and healthcare. As a leader in pharmaceutical education, he has received accolades for his role in fostering academia-industry collaboration, mentoring students, and advancing innovative research in biotechnology.

Research Focus

Abhay H Pande’s research focuses on the development of innovative biopharmaceutical solutions to address global healthcare challenges. His work primarily targets inflammatory disorders, cancer, and bioterrorism defense. Key innovations include the development of bispecific antibodies (BiSpekDAb™) and prophylactic biologics (LBUPON™). Pande’s research also explores enzyme-based therapies for cardiovascular disorders, cancer treatment, and nerve agent poisoning. He collaborates with national and international research institutions, focusing on creating sustainable, scalable solutions for biopharmaceutical challenges. His research not only addresses urgent healthcare needs but also aims to make significant contributions to global sustainability through biotechnology.

Publication Top Notes

Title: Membrane fluidity is a key modulator of membrane binding, insertion, and activity of 5-lipoxygenase

Citations: 141

Title: Conformational instability of the cholera toxin A1 polypeptide

Citations: 92

Title: Studies on a Doubleheaded Protease Inhibitor from Phaseolus mungo

Citations: 65

Title: Modulation of human 5-lipoxygenase activity by membrane lipids

Citations: 62

Title: The N-terminal α-helix of pancreatic phospholipase A2 determines productive-mode orientation of the enzyme at the membrane surface

Citations: 60